The triptan drug class dominates the market for approved prescription acute treatments for migraine. Despite the array of approved triptan options, most of them generic, new reformulations have launched over the past few years that provide incremental advantages over the standard of care, and novel nontriptan alternatives appear on the horizon. This content explores how newer therapies have fared in this highly generic market and provides important context for new players entering a large, still underserved, and commercially promising arena.
Questions Answered
Product Description
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.
Geographies: United States
Key drugs covered: sumatriptan (all formulations), Onzetra Xsail, eletriptan, frovatriptan, rizatriptan oral/ODT, Treximet, zolmitriptan oral/ODT, Zomig Nasal Spray, dihydroergotamine (nasal/injectable), Cambia